| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Revenue | $25.4M | — |
| R&D Expense | $137.3M | -13.5% |
| SG&A Expense | $63.4M | +29.0% |
| Operating Income | -$176.9M | +16.9% |
| Income Tax | $0 | — |
| Net Income | -$169.9M | +14.5% |
| EPS (Basic) | -$1.43 | +21.0% |
| EPS (Diluted) | -$1.43 | +21.0% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $69.3M | -65.4% |
| Accounts Receivable | $10.9M | — |
| Inventory | $25.9M | — |
| Current Assets | $100.7M | -55.2% |
| Total Assets | $129.5M | -43.5% |
| Current Liabilities | $62.0M | +23.2% |
| Total Liabilities | $62.0M | +19.8% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$170.5M | +1.5% |
| Capital Expenditures | $140K | -77.2% |
| Investing Cash Flow | -$140K | -100.0% |
| Financing Cash Flow | $39.3M | +3663.7% |
| Free Cash Flow | -$170.6M | +1.8% |
| Stockholders' Equity |
| $67.5M |
| -61.9% |